Introduction {#s1}
============

Gastric cancer (GC) is the fifth-most commonly diagnosed cancer and the third leading cause of cancer-related death in the world. In 2018, there were more than 1,000,000 new GC cases and GC resulted in an estimated 783,000 deaths ([@B4]). Despite the progress in diagnosis and treatment, the initial detection of most GC cases occurs at advanced stages, which leads to poor prognosis, with a median overall survival of 11 months ([@B22]). Currently, chemotherapy is widely used as the main treatment for GC. However, the side effects and the development of resistance to chemotherapy in clinical practice reveal its limitations and have prompted more attention to be paid to the study of complementary treatments ([@B3]).

Paclitaxel is a widely used second-line chemotherapy drug for advanced GC ([@B2]). However, it has a low response rate (16--22%) ([@B1]) and significant side effects (such as neutropenia and gastrointestinal adverse reactions) ([@B20]), so a paclitaxel-based combination regimen may be more beneficial.

Traditional Chinese medicines (TCMs), which can be used as complementary treatments for cancer patients, have been widely used in China for years ([@B23]; [@B5]). TCM combinations have been reported to alleviate chemotherapy drug resistance and enhance the efficacy of chemotherapy. However, it remains uncertain whether paclitaxel-based chemotherapy combined with TCMs is more effective than paclitaxel-based chemotherapy alone for GC.

In this study, we aimed to use a meta-analysis to summarize and analyze high-quality RCTs in order to evaluate the efficacy and safety of combination therapy using paclitaxel and TCMs compared to paclitaxel alone for GC. We further aimed to identify the most frequently used TCM herbal compounds in order to provide a reference for the selection of a reasonable TCM regimen for the treatment of GC.

Materials and Methods {#s2}
=====================

Study Selection {#s2_1}
---------------

Databases, comprising PubMed, EMBASE, Cochrane Library, Wanfang, Chinese Science and Technology Journals (CQVIP), and China Academic Journals (CNKI), were independently searched from their inceptions to September 25, 2019 by two reviewers (Yicong Li and Chunyue Yu). The search terms (in English and Chinese) involved the following: "paclitaxel OR Taxol" AND "Chinese herb OR traditional medicine" AND "stomach neoplasm OR gastric neoplasm OR stomach cancer OR gastric cancer". There was no restriction on the language. The Jadad scale was used to assess study quality ([@B11]).

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Studies were included if they met the following PICOS criteria: (1) participants: GC patients (diagnosed based on pathology results); (2) intervention: paclitaxel-based chemotherapy regimen combined with TCM; (3) comparator: paclitaxel-based chemotherapy regimen alone; (4) outcomes: tumor response rate (TRR), Karnofsky Performance Scale (KPS) score, and/or side effects (at least one of these outcomes); (5) study design: randomized controlled trial (RCT).

The exclusion criteria were as follows: (1) outcomes not reported clearly or appropriate data could not be extracted; (2) Jadad score \<2; (3) duplicate studies by the same authors.

Data Extraction {#s2_3}
---------------

All the included studies were screened independently by two reviewers (Yicong Li and Chunyue Yu) to extract the following data: first author (year), study period, sample sizes, tumor, node, metastasis (TNM) stage, TCM intervention, paclitaxel regimen, drug administration route, treatment duration, and outcomes. Any differences were resolved by discussion between the two reviewers, and differences that could not be resolved were settled by a third reviewer (Xinbing Sui).

Risk of Bias Assessment {#s2_4}
-----------------------

We used the Cochrane risk of bias tool ([@B9]) to assess the risk of bias of the RCTs. The domains of this tool include selection bias, performance bias, detection bias, attrition bias, and reporting bias. Low, high, and unclear risk of bias indicate that the study met the criteria, did not meet the criteria, and did not provide enough information to make a judgment, respectively.

Primary Outcomes {#s2_5}
----------------

Tumor response rate (TRR), containing the criteria of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), was the primary outcome. CR plus PR was also included as TRR. Subgroup analyses were then used to assess whether there was a difference in TRR between the paclitaxel+TCM and control groups in various subgroups of studies, according to administration route (studies were categorized into an oral administration subgroup in which TCMs were taken orally as a decoction or capsules \[seven studies\] or an injection subgroup \[six studies\]), TNM stage (studies were categorized into a stage IV-only subgroup \[two studies\] or other stages subgroup \[eleven studies\]), treatment duration (studies were categorized into ≤4 weeks \[four studies\], 4--8 weeks \[six studies\], and \>8 weeks \[three studies\] subgroups), and the three most commonly used TCM combinations (studies were categorized into overlapping subgroups depending on whether they used a combination of Dangshen and Gancao \[eight studies\], Dangshen, Gancao, Baizhu and Fuling \[seven studies\], or Dangshen, Gancao, Baizhu, Fuling, Chenpi, Shanyao, Yiyiren, and Sharen \[three studies\]).

Secondary Outcomes {#s2_6}
------------------

KPS score was used to assess quality of life (QOL). Improvement of QOL was defined as a KPS score increase of ≥10 points after treatment. Side effects, which included blood abnormalities (neutropenia, leukopenia, anemia, and thrombocytopenia), nausea and vomiting, hepatic dysfunction, and neurotoxicity, were also evaluated as secondary outcomes.

Data Analysis {#s2_7}
-------------

Cochrane Review Manager (RevMan) software version 5.3 was utilized for statistical analysis. Risk ratio (RR) with a 95% confidence interval (CI) for the dichotomous outcomes was used to estimate the pooled effects. Heterogeneity was estimated by Cochran\'s Q test and assessed using *I* ^2^. A fixed-effects model was used to estimate the pooled effect when heterogeneity was absent (*I* ^2^ \< 50%). Otherwise, a random-effects model was used. *p* \< 0.05 was considered significant. A funnel plot was used to assess publication bias regarding TRR data.

Results {#s3}
=======

Literature Search {#s3_1}
-----------------

As shown in [**Figure 1**](#f1){ref-type="fig"}, 237 articles were retrieved in the literature search. After removal of duplicate articles, 165 articles remained. After reviewing the titles and abstracts, 100 irrelevant articles were excluded. After adding two articles based on a review of the references of the remaining 65 articles, there were 67 articles. The full-text articles were then evaluated based on the inclusion and exclusion criteria, and 53 articles were excluded due to: Jadad score \<2 (n = 22), not being an RCT (n = 19), not providing a clear evaluation of tumor responses (n = 7), duplicate reports (n = 3), and comparator not based on paclitaxel (n = 2). Further details are shown in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. Fourteen articles were finally included in our meta-analysis.

![Flow diagram showing study selection for meta-analysis.](fphar-11-00132-g001){#f1}

Study Characteristics {#s3_2}
---------------------

The main characteristics of the 14 included studies are shown in [**Table 1**](#T1){ref-type="table"}. The publication years ranged from 2009 to 2018 and there were 1,109 included patients, with 502 in the paclitaxel+TCM group and 506 in the control group.

###### 

Characteristics of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author (Year)   Study Period   Sample size (T/C n)   TNM Stage                Drug Delivery   TCM Duration   TCM Intervention                                 Paclitaxel Regimen             TRR\
                                                                                                                                                                                                     (T/C n)
  --------------------- -------------- --------------------- ------------------------ --------------- -------------- ------------------------------------------------ ------------------------------ ---------
  [@B7]                 2005--2007     34/33                 IIIb: 23/24; IV: 11/9    Injection       6w             Huachansu injection                              TPF: PTX+PDD+5-FU              15/12

  [@B8]                 NR             20/20                 Advanced stage           Orally          8w             Jianpixiaozheng decoction                        TS: PTX+S-1                    10/9

  [@B10]                2015--2016     50/50                 Advanced stage           Injection       18w            Kanglaite injection + Jianpiyiqi decoction       TP: PTX+PDD                    35/20

  [@B12]                2015--2018     30/30                 IV                       Orally          6w             Shenlingbaizhu decoction                         TCF: PTX+CF+5-FU               NR

  [@B14]                2013--2014     25/25                 Advanced stage           Orally          4w             Rg3+Shenyi capsule                               TCF: PTX+CF+5-FU               17/11

  [@B13]                2007--2009     42/40                 Advanced stage           Orally          22d            Liujunzi decoction                               TCF: PTX+CF+5-FU               25/23

  [@B15]                2012--2015     33/32                 IV                       Injection       8w             Fufangkushen injection + Yiqiyangwei decoction   PTX                            27/18

  [@B16]                2014--2015     50/50                 Advanced stage           Orally          8w             Shenlingbaizhu decoction                         TS: PTX+S-1                    27/22

  [@B17]                2015--2016     31/31                 Advanced stage           Injection       4w             Kang\'ai injection                               PTX+CF                         27/19

  [@B18]                2006--2008     30/30                 IIIb: 17/14; IV: 13/16   Injection       20d            Aidi injection                                   TPF: PTX+PDD+5-FU              16/16

  [@B19]                2015--2016     50/50                 III: 34/36; IV: 16/14    Injection       12w            Fufangkushen injection                           PTX                            35/15

  [@B21]                2007--2011     40/46                 IV                       Orally          6w             Fufangbanmao capsule                             PTX+5-FU+LV                    19/12

  [@B25]                2013--2015     45/45                 Advanced stage           Orally          8w             Rg3                                              TCF: PTX+CF+5-FU               35/28

  [@B26]                2007--2008     22/24                 III:6/5; IV:16/19        Orally          24w            Fuzhenghewei liquid medicament                   TP: PTX+PDD/TCF: PTX+CF+5-FU   8/8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

T, treatment group; C, control group; TNM, cancer staging system; NR, not reported; TCM, traditional Chinese medicine, TRR, tumor response rate; w, week; d, day; PTX, paclitaxel; PDD, cisplatin; 5-FU, 5-fluorouracil; CF, calcium folinate; LV, leucovorin.

Risk of Bias and Methodological Quality {#s3_3}
---------------------------------------

We selected the risk of bias tool provided by the Cochrane Collaboration ([@B9]) to assess the risk of bias of the included studies. All of the included studies exhibited bias according to at least one of the bias categories. "Random" or "randomized" or "randomization" was mentioned in all 14 studies, along with descriptions of the specific randomization methods. One study reported allocation concealment and blinding of participants and healthcare providers, but there was unclear blinding of outcome assessment ([@B8]). One study lacked essential data TRR ([@B12]), while the other 13 studies reported detailed outcome data. None of the 14 studies provided clear descriptions of detection bias, reporting bias, or other bias. [**Figure 2**](#f2){ref-type="fig"} shows detailed overviews of the scores in each bias category for each study.

![Risk of bias summary and diagram. **(A)** Risk of bias summary: review of authors\' judgments about each risk of bias item for all included studies. **(B)** Risk of bias diagram: review of authors\' judgments about each risk of bias item presented as percentages across all included studies. Red, green, and yellow indicate high, low, and unclear risk of bias, respectively.](fphar-11-00132-g002){#f2}

Meta-Analysis of TRR {#s3_4}
--------------------

We extracted the TRR data from 13 of the 14 included studies. The fixed-effects meta-analysis showed that the TRR was significantly improved in the paclitaxel+TCM group compared to the control group (RR: 1.39; 95% CI: 1.24--1.57; *p* \< 0.001, *I* ^2^ = 12%) ([**Figure 3**](#f3){ref-type="fig"}).

![Forest plot of meta-analysis of tumor response rate (TRR) (all studies and subgroups of studies: oral administration subgroup, injection subgroup).](fphar-11-00132-g003){#f3}

Regarding the administration route subgroup analysis, the TRR was significantly enhanced in the paclitaxel+TCM group compared with the control group in the oral administration subgroup (seven studies; RR: 1.55; 95% CI: 1.31--1.84; *p* \< 0.001, *I* ^2^ = 0%) and the injection subgroup (six studies; RR: 1.24; 95% CI: 1.05--1.47; *p* \< 0.05, *I* ^2^ = 0%) ([**Figure 3**](#f3){ref-type="fig"}).

Regarding the TNM subgroup analysis, the TRR was significantly improved in the paclitaxel+TCM group compared with the control group in the stage IV-only subgroup (two studies; RR: 1.59; 95% CI: 1.16--2.18; *p* \< 0.01, *I* ^2^ = 0%) and the other stages subgroup (eleven studies; RR: 1.36; 95% CI: 1.20--1.55; *p* \< 0.001, *I* ^2^ = 20%) ([**Figure 4**](#f4){ref-type="fig"}).

![Forest plot of subgroup meta-analysis of TRR according to TNM stages.](fphar-11-00132-g004){#f4}

Regarding the treatment duration subgroup analysis, there were no significant effects on TRR in the ≤4 weeks subgroup (four studies; RR: 1.21; 95% CI: 0.99--1.48; *p* = 0.06, *I* ^2^ = 6%), but there was significant improvement in the 4--8 weeks subgroup (six studies; RR: 1.33; 95% CI: 1.12--1.58; *p* \< 0.01, *I* ^2^ = 0%) and the \>8 weeks subgroup (three studies; RR: 1.84; 95% CI: 1.39--2.42; *p* \< 0.001, *I* ^2^ = 28%) ([**Figure 5**](#f5){ref-type="fig"}).

![Forest plot of subgroup meta-analysis of TRR according to treatment duration.](fphar-11-00132-g005){#f5}

Meta-Analysis of KPS {#s3_5}
--------------------

The fixed-effects meta-analysis showed a significant difference between the two groups in the rate of KPS improvement (≥10 points) (four studies; RR: 1.53; 95% CI: 1.19--1.96; *p* \< 0.001, *I* ^2^ = 0%) ([**Figure 6**](#f6){ref-type="fig"}). The KPS was significantly higher in the paclitaxel+TCM group than the control group. The results indicated that, compared with paclitaxel-based chemotherapy alone, combined therapy with TCMs can significantly improve the QOL of patients with GC.

![Forest plot of meta-analysis of improvement in Karnofsky Performance Scale (KPS) score (≥10 points).](fphar-11-00132-g006){#f6}

Meta-Analysis of Blood Abnormalities {#s3_6}
------------------------------------

The fixed-effects meta-analyses showed significant decreases in the paclitaxel+TCM group in the rate of neutropenia (five studies; RR: 0.68; 95% CI: 0.55--0.84; *p* \< 0.001, *I* ^2^ = 44%), the rate of leukopenia (four studies; RR: 0.69; 95% CI: 0.54--0.90; *p* \< 0.01, *I* ^2^ = 40%), and the rate of thrombocytopenia (six studies; RR: 0.66; 95% CI: 0.46--0.96; *p* \< 0.05, *I* ^2^ = 32%) ([**Figure 7**](#f7){ref-type="fig"}). The rate of anemia did not differ significantly (five studies; RR: 0.65; 95% CI: 0.40--1.04; *p*= 0.07, *I* ^2^ = 0%) ([**Figure 7**](#f7){ref-type="fig"}). The results showed that paclitaxel-based chemotherapy combined with TCMs significantly reduced the rate of neutropenia, leukopenia, and thrombocytopenia, but had no significant effect on the rate of anemia during the treatment of GC.

![Forest plot of meta-analysis of blood abnormalities.](fphar-11-00132-g007){#f7}

Meta-Analysis of Nausea and Vomiting, Hepatic Dysfunction, and Neurotoxicity {#s3_7}
----------------------------------------------------------------------------

The random-effects meta-analysis showed a significantly lower rate of nausea and vomiting in the paclitaxel+TCM group compared to the control group (eight studies; RR: 0.50; 95% CI: 0.32--0.80; *p* \< 0.01, *I* ^2^ = 85%). However, there were no significant differences in hepatic dysfunction (three studies; RR: 0.63; 95% CI: 0.33--1.20; *p* = 0.16, *I* ^2^ = 0%) or neurotoxicity (three studies; RR: 0.64; 95% CI: 0.26--1.55; *p* = 0.32, *I* ^2^ = 0%) ([**Figure 8**](#f8){ref-type="fig"}). Regarding the analysis of nausea and vomiting, a random-effects model was used to calculate the pooled RR (and 95% CI) due to significant heterogeneity (*p* \< 0.001, *I* ^2^ = 72%). These results indicated that paclitaxel combined with TCMs can significantly reduce nausea and vomiting compared to paclitaxel-based chemotherapy alone, without causing additional hepatic dysfunction or neurotoxicity.

![Forest plot of meta-analysis of nausea and vomiting, hepatic dysfunction, and neurotoxicity.](fphar-11-00132-g008){#f8}

TCM Formulae and Frequently Used Herbal Compounds {#s3_8}
-------------------------------------------------

Among the studies in the oral administration subgroup that used multi-ingredient TCM regimens, there were eight studies with a total of 29 TCM ingredients. Nine of these ingredients were used in four or more formulations. Ordered according to their frequency of use, the TCMs were as follows: Dangshen (n = 8), Gancao (n = 8), Baizhu (n = 7), Fuling (n = 7), Chenpi (n = 5), Banxia (n = 4), Shanyao (n = 4), Yiyiren (n = 4), and Sharen (n = 4) ([**Table 2**](#T2){ref-type="table"} and [**Figure 9**](#f9){ref-type="fig"}). Using fixed-effects models, we performed a subgroup analysis of the three most commonly used combinations. Regarding the subgroup involving the combination of Dangshen and Gancao, TRR was significantly improved in the paclitaxel+TCM group compared to the control group (eight studies; RR: 1.44; 95% CI: 1.22--1.70; *p* \< 0.001, *I* ^2^ = 40%). Moreover, regarding the subgroup involving the combination of Dangshen, Gancao, Baizhu and Fuling, there was a significant improvement (seven studies; RR: 1.31; 95% CI: 1.09--1.56; *p* \< 0.01, *I* ^2^ = 0%). Furthermore, regarding the subgroup involving the combination of Dangshen, Gancao, Baizhu, Fuling, Chenpi, Shanyao, Yiyiren, and Sharen, there was also a significant improvement (three studies; RR: 1.30; 95% CI: 1.20--1.41; *p* \< 0.001, *I* ^2^ = 0%).

###### 

Name of High Frequency TCMs.

  Chinese Name   Pharmaceutical name                    Family            No. of Studies
  -------------- -------------------------------------- ----------------- ----------------
  Dangshen       *Codonopsis Radix*                     *Campanulaceae*   8
  Gancao         *Glycyrrhizae Radix et Rhizoma*        *Leguminosae*     8
  Baizhu         *Atractylodis Macrocephalae Rhizoma*   *Asteraceae*      7
  Fuling         *Poria*                                *Polyporaceae*    7
  Chenpi         *Citri Reticulatae Pericarpium*        *Rutaceae*        5
  Shanyao        *Dioscoreae Rhizoma*                   *Dioscoreaceae*   4
  Yiyiren        *Coicis Semen*                         *Gramineae*       4
  Sharen         *Amomi Fructus*                        *Zingiberaceae*   4
  Banxia         *Pineelliae Rhizoma*                   *Araceae*         4

![Traditional Chinese medicine (TCM) herbal compounds used in each study.](fphar-11-00132-g009){#f9}

Publication Bias {#s3_9}
----------------

A funnel plot of the 13 studies that reported TRR data was used to assess publication bias ([**Figure 10**](#f10){ref-type="fig"}). The funnel plot was asymmetrical, indicating the existence of publication bias.

![Funnel plot assessing publication bias regarding TRR.](fphar-11-00132-g010){#f10}

Discussion {#s4}
==========

Paclitaxel, which is a representative second-line chemotherapy drug for GC, is generally recognized as being able to inhibit cancer ([@B27]). However, because of its stronger side effects compared with the first-line chemotherapy drugs, it represents a double-edged sword in GC treatment. This has become an urgent problem to be solved, potentially with TCM combination therapy. Our study showed that, overall, paclitaxel+TCM significantly improved the TRR in GC patients, and it particularly improved the TRR in the subgroups of studies that used oral administration of TCM, included only stage IV patients, and had a long treatment duration. As the primary outcome, TRR can directly reflect the efficacy of chemotherapy regimens on tumors. A meta-analysis by [@B24] also showed that TCM (Huachansu) combined with chemotherapy increased the TRR in patients with GC, which is consistent with our findings. In addition, it is necessary to assess QOL to evaluate the effects of chemotherapy combined with TCMs. Among the included studies, four reported the number of patients in each group with a KPS increase ≥10 points. We evaluated the dichotomous variable (KPS improvement) in the meta-analysis, which showed a positive result in the paclitaxel+TCM group compared to the control group.

In addition to enhancing the effect of chemotherapy, combining chemotherapy with TCMs can reduce the side effects and decrease mild drug resistance. Accordingly, our study comprehensively compared the side effects of the two regimens. The blood abnormality results showed that the paclitaxel+TCM group reduced the rates of neutropenia, leukopenia, and thrombocytopenia. Paclitaxel+TCM also alleviated nausea and vomiting after chemotherapy, which shows the positive effect of TCMs on the gastrointestinal system. Furthermore, given that there are a few reports on the adverse effects of TCMs, we evaluated negative effects related to hepatic dysfunction and neurotoxicity. It is gratifying to note that the paclitaxel+TCM group had fewer cases of hepatic dysfunction and neurotoxicity than the groups involving paclitaxel-based chemotherapy alone.

To discern the commonalities between the TCM formulae that were combined with paclitaxel in the various studies, we analyzed the frequency and compatibility of the oral Chinese herbal compounds in the included studies. As the most effective qi tonic among the administered TCMs, the combination of Dangshen and Gancao was used in all eight studies in the oral administration subgroup that used multi-ingredient TCM regimens. In addition, seven of these studies (87.5%) used a combination of Dangshen, Gancao, Baizhu and Fuling, which is the most representative basic qi tonic TCM formula and is known as Sijunzi Decoction. According to these findings, we can infer that when treating GC using paclitaxel-based chemotherapy combined with TCMs, most of the studies invigorated the qi and strengthened the spleen as the standard treatment approach. This is also supported by the existing evidence on TCM treatment for advanced GC and TCMs combined with chemotherapy ([@B6]). In addition, we found a frequently recurring combination of eight ingredients (Dangshen, Gancao, Baizhu, Fuling, Chenpi, Shanyao, Yiyiren, and Sharen). This combination could be used to guide the prescribing of TCMs in paclitaxel+TCM regimens for the clinical treatment of GC and can be used as a candidate treatment for further RCTs.

An advantage of our study was the use of strict inclusion and exclusion criteria, excluding studies with Jadad scale \<2 to improve the quality of the meta-analysis. Furthermore, we not only systematically searched the databases (from their inceptions) for studies in English, but we also searched the databases in Chinese; therefore, the included literature was not limited to English. Additionally, we comprehensively evaluated and compared the side effects of paclitaxel+TCM with paclitaxel-based chemotherapy alone. The results indicate that paclitaxel+TCM is more effective and safer. Finally, we discovered a frequently used combination of herbal compounds, which should be assessed in future RCTs.

Our research has several limitations. There was a lack of large, multicenter, standardized RCTs, and our included studies were mostly small, which may have led to some bias in the outcomes. We look forward to more high-quality RCTs being published in international journals. Moreover, the included studies lacked assessment of the efficacy of paclitaxel+TCM regimens in paclitaxel-resistant patients. In the future, we plan to focus on drug resistance in order to facilitate a more comprehensive evaluation of the role of TCMs in combination therapies.
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